COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
enVVeno Medical Corporation to present abstract on VenoValve for venous disease treatment at SCVS Symposium. Potential FDA decision in 2025. CVI impact and Company overview -
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
enVVeno Medical Corporation reports Q4 cash burn of $5.2 million in line with projections. PMA application for VenoValve submitted, FDA decision in H2 2025 -
-
-
COMMUNIQUÉ DE PRESSE
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
enVVeno Medical announces sustained improvements in venous disease treatment with the VenoValve one year after pivotal trial results. Pivotal trial data presented at the 37th Annual Meeting of the American Venous Forum highlights statistically significant improvements in quality of life indicators. FDA decision expected in late 2025
